The First Drug for a Disease That Had Zero

The road wasn't smooth. Minoryx submitted its first EMA marketing application in September 2022, and that initial filing was turned down in 2024. The company came back with new data, this time built on the NEXUS pediatric trial, and refiled. The CHMP (the EMA's scientific committee) gave a positive opinion in July 2026, and the European Commission made it official in September.

That kind of persistence matters. Plenty of biotech companies fold after a first regulatory rejection. Minoryx went back to the drawing board and found a path through.

What the Data Actually Shows

The approval leans heavily on the NEXUS study, which tested leriglitazone in pediatric cALD patients. The results were striking for a disease where "do nothing" is often the grim default.

All 20 evaluable patients remained clinically stable during the study. Even more notable: 35% met the criteria for arrested disease, compared to a historical self-arrest rate of just 10%. In a disease that tends to steamroll forward, stabilization is a big deal.

The approved label is precise. NEZGLYAL is indicated for males aged 2 to 12 years with ALD who have brain lesions visible on MRI but without active inflammation (gadolinium-negative), and who still have minimal neurological impairment (a Neurological Functional Score of 0 or 1). Translation: it's for catching the disease early, before the worst damage is done.

On the safety side, the profile looked favorable. In earlier studies, serious adverse events actually occurred less frequently with leriglitazone (18%) than with placebo (26%). The most common serious event, clinically progressive cALD, showed up only in the placebo group.

Why This Matters Beyond One Drug

Neurodegenerative diseases are the graveyard of drug development. Historically, the failure rate for disease-modifying therapies in this space has been described as "nearly 100%." Most approved treatments for conditions like Alzheimer's and Parkinson's just manage symptoms; they don't slow the underlying disease.

Recent years have finally cracked that streak, mostly thanks to Alzheimer's therapies like lecanemab (approved 2023) and donanemab (approved 2024). But those are blockbuster-scale programs backed by pharma giants targeting millions of patients. NEZGLYAL is something different: a small biotech, a tiny patient population, and a disease most people have never heard of.

The broader signal here is that first-in-disease approvals for rare neurodegenerative conditions are possible, even when the commercial opportunity looks modest. CNS drugs historically get approved at less than half the rate of non-CNS drugs, and phase II/III failure rates in neuroscience hover around 85%. Every win in this space is hard-earned.

The Business Question Nobody's Asking Yet

The commercial picture for NEZGLYAL is complicated. The eligible patient pool is small by design: boys aged 2 to 12, early-stage disease, specific MRI criteria. That's a narrow funnel.

But it's also an oral medication for a very rare pediatric disease with zero existing drug competition. That profile typically commands premium orphan-drug pricing, though Minoryx and its commercial partner Neuraxpharm Group haven't disclosed numbers yet. Peak sales will hinge on diagnosis rates (newborn screening programs are still rolling out in many countries), specialist center adoption, and the always-thorny question of national reimbursement decisions across EU member states.

The bull case writes itself: first mover, no competition, devastating unmet need. The bear case is equally clear: tiny addressable market, reimbursement uncertainty, and an approval under exceptional circumstances (meaning the EC may require additional post-marketing data).

The Bigger Picture

For the families who've spent years watching this disease with no pharmacological options, September 21 wasn't just a regulatory milestone. It was the day the medicine cabinet stopped being empty.

Leriglitazone won't cure cALD. It won't replace stem cell transplants entirely. But it gives doctors a tool they've never had before: a pill that can be given early, without the risks of a major transplant procedure, to a child whose brain is quietly under siege.

In a therapeutic area famous for failure, that's not nothing. That's everything.